February 12, 2024Open Access

TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

View Full Paper

Ask AI

Bookmark

Abstract

Tumor response according to RECIST v1.1 (investigator assessment) in response-evaluable patients

No takes yet. Share an insight, caveat, or question.

Subbiah et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark